allogeneic– tag –
-
REPROCELL Unveils StemEdit Hypoimmune iPSCs with HLA Knockout, Accelerating Development of Off-the-Shelf Cell Therapies
REPROCELL (Blog) Japan Overview REPROCELL has announced the launch of its StemEdit hypoimmune iPSC lines, featuring HLA knockout through high-efficiency genome editing and regulatory-compliant cell lines. This technology aims to mitigate... -
Chivanta Analysis: Allogeneic CAR-T Surpasses Autologous in Scalable Manufacturing and Immediate Availability, Spotlighting Fate Therapeutics’ iPSC Platform
Chivanta USA Overview Chivanta's analysis indicates allogeneic CAR-T therapies hold significant advantages over autologous CAR-T, particularly in scalable manufacturing, immediate availability, and product consistency. Companies like All... -
Drug Discovery News Identifies Critical Bottlenecks in Cell & Gene Therapy Manufacturing: Low Viral Vector Purification Yields and Plasmid DNA Supply Shortages
Drug Discovery News USA Overview Drug Discovery News highlights severe bottlenecks in cell and gene therapy (CGT) manufacturing, specifically in viral vector production. Low downstream purification yields for adeno-associated virus (AAV)... -
Cellistic Launches Integrated CDMO Services for iPSC-Derived Allogeneic Cell Therapies, Streamlining Development to GMP Manufacturing
Cellistic USA Overview Cellistic has introduced comprehensive CDMO services for iPSC-derived cell therapy manufacturing, covering development through GMP production. Their bioreactor-based Cellistic Echo platforms are engineered to ensur... -
Imunopharm Files for Shanghai STAR Market IPO, Targeting $550 Million Valuation to Expand CAR-T and CDMO Business
VCBeat China Overview Chinese biotechnology firm Imunopharm has filed for an Initial Public Offering (IPO) on the Shanghai STAR Market, targeting a valuation of 4 billion RMB (approximately $550 million). The company's pipeline includes ... -
FDA Approves Orca Bio’s Tregzi to Reduce GvHD Incidence and Improve Outcomes in Blood Cancer Patients Undergoing Allogeneic HSCT
Precision Oncology News USA Overview The U.S. FDA has approved Orca Bio's precision-engineered donor-derived cell therapy, Tregzi. Tregzi aims to significantly reduce the incidence of graft-versus-host disease (GvHD) while maintaining th... -
Addressing Bottlenecks in Cell and Gene Therapy Manufacturing: Urgent Need for Quality Control and Supply Chain Optimization
Drug Discovery News USA Overview Cell and gene therapy (CGT) manufacturing faces significant bottlenecks, particularly in autologous cell therapies, due to logistical delays and complex quality control challenges. Frequent issues arise w... -
Sana Biotechnology Advances Phase 1 Clinical Trial for Immunosuppression-Free iPSC-Derived Islet Cell Therapy UP421 for Type 1 Diabetes
AAII USA Overview Sana Biotechnology is actively progressing its Phase 1 clinical trial for UP421, an allogeneic islet cell product engineered with its Hypoimmune Platform (HIP) technology for type 1 diabetes, aiming to eliminate the nee... -
UniXell Biotechnology Secures FDA IND Clearance for iPSC Parkinson’s Therapy UX-DA003, Achieving Dual Breakthrough in China and U.S.
BioInformant China Overview UniXell Biotechnology has secured FDA IND clearance for UX-DA003, an iPSC-derived Parkinson's disease therapy, marking a dual breakthrough in both China and the U.S. UX-DA003 is an allogeneic iPSC-derived midb... -
Histocell Accelerates Advanced Cell Therapy Production with New 800m² GMP Facility, Targeting 1,200 Annual Batches
REPROCELL Spain Overview Histocell has inaugurated an 800m² Advanced Therapies GMP facility, dramatically increasing its cell manufacturing capacity to an estimated 1,200 batches annually for both autologous and allogeneic treatments. Th...
